Driftstatus

Nyheter i Janusmed

Janusmed

Driftstatus

Nyheter i Janusmed

CYMBALTA (Enterokapsel, hård), amitriptylin
  • CYMBALTA (Enterokapsel, hård)
  • amitriptylin
Rensa sökning

7/17/2025

Janusmed interaktioner

Interaktioner

Startsida interaktioner

Aktuellt

Användarhandledning

E-utbildning

CYP3A4-hämmare/inducerare

FAQ

Skriv ut

Administreringssätt

Skriv ut

1 interaktion mellan valda läkemedel
Lägg till
Rensa tillval
Läkemedel / substans
Interaktioner
amitriptylin (Enteral och parenteral)

110

CYMBALTA (Enterokapsel, hård)
duloxetin (Enteral peroral)

160

C0 C0
C0 C0

duloxetin - amitriptylin

duloxetin - amitriptylin

Klass : C0

Visa all info

Skriv ut

Kontakta oss

  1. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997;43:137-44.

  2. Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology (Berl). 2000;147:378-83.

  3. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit. 1992;14:1-8.

  4. Cymbalta (duloxetine). ELI LILLY AND COMPANY Indianapolis, Indiana 46 285, U.S.A. Pharmaca Fennica. Helsinki: Pharmaceutical Information Centre . 2006.

  5. Duloxetine (Yentreve). Eli Lilly. EPAR Scientific discussion. 2006.

  6. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170-7.

  7. Hua TC, Pan A, Chan C, Poo YK. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2004;57:652-6.

  1. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997;43:137-44.
  2. Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology (Berl). 2000;147:378-83.
  3. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit. 1992;14:1-8.
  4. Cymbalta (duloxetine). ELI LILLY AND COMPANY Indianapolis, Indiana 46 285, U.S.A. Pharmaca Fennica. Helsinki: Pharmaceutical Information Centre . 2006.
  5. Duloxetine (Yentreve). Eli Lilly. EPAR Scientific discussion. 2006.
  6. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170-7.
  7. Hua TC, Pan A, Chan C, Poo YK. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2004;57:652-6.